Lozada, Keeran Aziel S.

HRN: 24-14-71  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2023
AMPICILLIN 250MG (VIAL)
11/30/2023
12/08/2023
IV
90mg
Q12
Psnb
Waiting Final Action 
11/30/2023
GENTAMICIN 40MG/ML, 2ML (AMP)
11/30/2023
12/07/2023
IV
9mg
Q36h
Psnb
Waiting Final Action 
12/03/2023
CEFOTAXIME 500MG (VIAL)
12/03/2023
12/09/2023
IVT
90mg
Q12
Preterm,psnb
Waiting Final Action 
12/05/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/05/2023
12/15/2023
IV
180mg
Q12
PSNB
Waiting Final Action 
12/13/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/13/2023
12/16/2023
IV
180mg
Q12h
PSNB
Waiting Final Action 
12/13/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/13/2023
12/16/2023
IV
180mg
OD
Extended For 10 Days; PSNB
Waiting Final Action 
12/19/2023
CIPROFLOXACIN 500MG (TAB)
12/19/2023
12/26/2023
PER OREM
30mg/pptab
Bid
Potentially Septic Newborn
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: